Abstract: Devices and methods for administering a medication in fluid form, the systems and methods including a basal flow path and a bolus flow path in parallel to the basal flow path. The bolus flow path comprises a first check valve, a second check valve downstream of the first check valve, a piston pump disposed between the first valve and the second valve, and a pilot operated valve in parallel to the piston pump.

Abstract: Devices and methods for administering a medication in fluid form, the systems and methods including a basal flow path and a bolus flow path in parallel to the basal flow path. The bolus flow path includes a combined piston pump and rotatable valve. The piston pump is configured to prevent partial dosing of a bolus dose.

Abstract: A three-dimensional printer for the additive manufacturing of a part is provided. The printer includes a build platen, a pre-extrusion system, and a print head located downstream of the pre-extrusion system and configured to receive and deposit a filament. The print head includes a receiving section configured to receive the filament, an outlet through which the filament is deposited onto the build platen or a previously added layer of a part, a feeding mechanism constructed and arranged to feed the filament into the outlet, and a path length adjustment system positioned on the print head disposed between the pre-extrusion system and the feeding mechanism. The path length adjustment system constructed and arranged to create slack in the filament being delivered from the pre-extrusion system. Path length adjustment devices incorporating sliding components and flexure components are also disclosed.

Abstract: Systems and methods for network quality testing are provided. Synthetic traffic may be sent through a first flow path and a second flow path. The second flow path includes a portion apportionable to the first flow path, internal to a server, and a portion apportionable to an external flow path, external to the server. Durations of traffic traveling through the first flow path and the second flow path are compared to determine the portion of the second flow path apportionable to the external flow path. In an example, time stamping may be performed by component(s) of the server, such as a kernel, to determine the durations of the traffic traveling through the first flow path and the second flow path.

Abstract: Devices and methods for administering a medication in fluid form, the systems and methods including a basal flow path and a bolus flow path in parallel to the basal flow path. The bolus flow path includes a combined piston pump and rotatable valve. The piston pump is configured to prevent partial dosing of a bolus dose.

Abstract: Devices and methods for administering a medication in fluid form, the systems and methods including a basal flow path and a bolus flow path in parallel to the basal flow path. The bolus flow path includes an inlet check valve, a first outlet check valve downstream of the inlet check valve, and a piston pump disposed between the inlet check valve and the first outlet check valve. The piston pump is configured to prevent partial dosing of a bolus dose.

Abstract: Devices and methods for administering a medication in fluid form, the systems and methods including a basal flow path and a bolus flow path in parallel to the basal flow path. The bolus flow path includes an inlet check valve, a first outlet check valve downstream of the inlet check valve, and a piston pump disposed between the inlet check valve and the first outlet check valve. The piston pump is configured to prevent partial dosing of a bolus dose.

Abstract: A railroad tie stacker arrangement includes means for conveying ties to a tie accumulation deck to form a layer of parallel ties, means for conveying the layer of parallel ties onto a stack accumulation lift, and means for lowering the stack accumulation lift as each successive layer of ties is deposited onto the lift.

Abstract: Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.

Abstract: Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.

Abstract: Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.

Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose or treat diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.

Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose or treat diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.